Integrating Liver-Chip data into pharmaceutical decision-making processes

References

• Center for Drug Evaluation and Research & Center for Biologics Evaluation and Research. Guidance for industry drug-induced Liver injury: premarketing clinical evaluation. Drug-induced Liver injury: premarketing clinical evaluation (2009). Available from: https://www.fda.gov/media/116737/download
   Google Scholar
• Siramshetty VB, Nickel J, Omieczynski C. Withdrawn—a resource for withdrawn and discontinued drugs. Nucleic Acids Res. 2015;44:D1080–D1086. doi: 10.1093/nar/gkv1192
   PubMed Web of Science ®Google Scholar
• Onakpoya IJ, Heneghan CJ, Aronson JK. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature. BMC Med. 2016;14(1):10. doi: 10.1186/s12916-016-0553-2
   PubMed Web of Science ®Google Scholar
• David S, Hamilton JP. Drug-induced Liver injury. US Gastroenterol Hepatol Rev. 2010;6:73–80.
   PubMedGoogle Scholar
• Thakkar S, Chen M, Fang H, et al. The liver toxicity knowledge base (LKTB) and drug-induced liver injury (DILI) classification for assessment of human liver injury. Exp Rev Gastroenterol Hepatol. 2017;12:31–38. doi: 10.1080/17474124.2018.1383154
   PubMed Web of Science ®Google Scholar
• Wadman M. FDA no longer needs to require animal tests before human drug trials. Science. 2003;379:127–128. doi: 10.1126/science.adg6276
   Google Scholar
• Junod SW FDA and clinical drug trials: a short history. FDA and clinical drug trials: a short history (2009). Available at: https://www.fda.gov/media/110437/download. (Accessed: 15th Jun 2023)
   Google Scholar
• Swaters D, van Veen A, Ritskes-Hoitinga M, et al. A history of regulatory animal testing: what can we learn? Altern Lab Anim. 2022;50:322–329. doi: 10.1177/02611929221118001
   PubMed Web of Science ®Google Scholar
• DeKeyser JG. Shou M species differences of drug-metabolizing enzymes. Encyclopedia Of Drug Metabolism And Interactions. 2012. doi: 10.1002/9780470921920.edm005
   Google Scholar
• Scannell JW, Bosley J, Hickman JA, et al. Predictive validity in drug discovery: what it is, why it matters and how to improve it. Nat Rev Drug Discov. 2022;21(12):915–931. doi: 10.1038/s41573-022-00552-x
   PubMed Web of Science ®Google Scholar
• Sun D, Gao W, Hu H, et al. Why 90% of clinical drug development fails and how to improve it? Acta Pharm Sin B. 2022;12:3049–3062. doi: 10.1016/j.apsb.2022.02.002
   PubMed Web of Science ®Google Scholar
• Valentin JP, Redfern WS. Prevalence, frequency, and impact of safety related issues throughout the pharmaceutical life cycle. The Toxicologist. 2017. Abstract Number 1722. https://www.toxicology.org/pubs/docs/tox/2017tox.pdf
   Google Scholar
• Akhtar A. A the flaws and human harms of animal experimentation. Camb Q Healthc Ethics. 2015;24:407–419. doi: 10.1017/S0963180115000079
   PubMed Web of Science ®Google Scholar
• Pound P, Ritskes-Hoitinga M. Ritskes-Hoitinga M is it possible to overcome issues of external validity in preclinical animal research? Why most animal models are bound to fail. J Transl Med. 2018;16: doi: 10.1186/s12967-018-1678-1
   PubMed Web of Science ®Google Scholar
• Ingber DE. Is it time for reviewer 3 to request human organ chip experiments instead of animal validation studies? Adv Sci. 2020;7(22):2002030. doi: 10.1002/advs.202002030
   Web of Science ®Google Scholar
• Matthews RA. Medical progress depends on animal models - doesn’t it? J R Soc Med. 2008;101:95–98. doi: 10.1258/jrsm.2007.070164
   PubMed Web of Science ®Google Scholar
• Bailey J, Thew M, Balls M. An analysis of the use of animal models in predicting human toxicology and drug safety. Altern Lab Anim. 2014;42:181–199.
   PubMed Web of Science ®Google Scholar
• Jang KJ, Otieno MA, Ronxhi J, et al. Reproducing human and cross-species drug toxicities using a liver-chip. Sci, trans med. 2019;11(517):eaax5516. doi: 10.1126/scitranslmed.aax5516
   PubMed Web of Science ®Google Scholar
• Jang KJ, Mehr AP, Hamilton GA, et al. Human kidney proximal tubule-on-a-chip for drug transport and nephrotoxicity assessment. Integr Biol. 2013;5(9):1119–1129. doi: 10.1039/c3ib40049b
   Google Scholar
• Apostolou A, Panchakshari RA, Banerjee A, et al. A novel microphysiological colon platform to decipher mechanisms driving human intestinal permeability. Cell Mol Gastroenterol Hepatol. 2021;12(5):1719–1741. doi: 10.1016/j.jcmgh.2021.07.004
   PubMed Web of Science ®Google Scholar
• Kerns SJ, Belgur C, Petropolis D, et al. Human immunocompetent Organ-on-Chip platforms allow safety profiling of tumor-targeted T-cell bispecific antibodies. Elife. 2021;10:e67106. doi: 10.7554/eLife.67106
   PubMed Web of Science ®Google Scholar
• Pediaditakis I, Kodella KR, Manatakis DV, et al. A microengineered Brain-Chip to model neuroinflammation in humans. iScience. 2022;25:104813. doi: 10.1016/j.isci.2022.104813
   PubMed Web of Science ®Google Scholar
• Ingber DE. Human organs-on-chips for disease modelling, drug development and personalized medicine. Nat Rev Genet. 2022;23(8):467–491. doi: 10.1038/s41576-022-00466-9
   PubMed Web of Science ®Google Scholar
• Low L, Mummery C, Berridge BR, et al. Organs-on-chips: into the next decade. Nat Rev Drug Discov. 2021;20(5):345–361. doi: 10.1038/s41573-020-0079-3
   PubMed Web of Science ®Google Scholar
• Ewart L, Apostolou A, Briggs SA, et al. Performance assessment and economic analysis of a human liver-chip for predictive toxicology. Commun Med. 2022;2(1):154. doi: 10.1038/s43856-022-00209-1
   PubMedGoogle Scholar
• Baudy AR, Otieno MA, Hewitt P, et al. Liver microphysiological systems development guidelines for safety risk assessment in the pharmaceutical industry. Lab Chip. 2019;20:215–225.
   PubMed Web of Science ®Google Scholar
• Fabre K, Berridge B, Proctor WR, et al. Introduction to a manuscript series on the characterization and use of microphysiological systems (MPS) in pharmaceutical safety and ADME applications. Lab Chip. 2020;20(6):1049–1057. doi: 10.1039/C9LC01168D
   PubMed Web of Science ®Google Scholar
• Vargas HM, Rolf MG, Wisialowski TA, et al. Time for a fully integrated nonclinical–clinical risk assessment to streamline QT prolongation liability determinations: a pharma industry perspective. Clin Pharmacol Ther. 2020;109:310–318. doi: 10.1002/cpt.2029
   PubMed Web of Science ®Google Scholar
• Garside H, Marcoe KF, Chestnut-Speelman J, et al. Evaluation of the use of imaging parameters for the detection of compound-induced hepatotoxicity in 384-well cultures of HEPG2 cells and cryopreserved primary human hepatocytes. Toxicol In Vitro. 2014;28:171–181.
   PubMed Web of Science ®Google Scholar
• Organ-Chip Model – Liver-Chip. Emulate Inc. https://emulatebio.com/liver-chip/ [cited 31 Aug, 2023]
   Google Scholar
• Shi Q, Arefin A, Ren L, et al. Co‐culture of human primary hepatocytes and nonparenchymal liver cells in the Emulate® Liver‐Chip for the study of drug‐induced liver injury. Curr Protoc. 2022;2(7):2;e478. doi: 10.1002/cpz1.478
   Google Scholar
• Sántha M. Biologia futura: animal testing in drug development—the past, the present and the future. Biologia Futura. 2020;71(4):443–452. doi: 10.1007/s42977-020-00050-4
   PubMedGoogle Scholar
• S.5002 - 117th congress (2021-2022): FDA Modernization act 2.0. S.5002 - FDA Modernization act 2.0 (2022). Available at: https://www.congress.gov/bill/117th-congress/senate-bill/5002. (cited 15th Jun 2023)
   Google Scholar
• Sewell F, Edwards J, Prior H, et al. Opportunities to apply the 3Rs in safety assessment programs. ILAR J. 2016;57(2):234–245. doi: 10.1093/ilar/ilw024
   PubMed Web of Science ®Google Scholar
• Baran S, Brown PC, Baudy AR, et al. Perspectives on the evaluation and adoption of complex in vitro models in drug development: workshop with the FDA and the pharmaceutical industry (IQ MPS Affiliate). ALTEX. 2022;39(2):297–314. doi: 10.14573/altex.2112203
   PubMedGoogle Scholar